Connections Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2025-12-04 pm EST 5-day change 1st Jan Change
166.91 USD -0.11% Intraday chart for Jazz Pharmaceuticals plc -5.66% +35.53%

46

Listed companies

7

Private companies

79

Insiders

Relation chart of related listed companies: Jazz Pharmaceuticals plc

Active Relations

Past Relations

Related listed companies: Jazz Pharmaceuticals plc

Active Relations

Past Relations

Relationship chart for related private companies: Jazz Pharmaceuticals plc

Active Relations

Past Relations

Related private companies: Jazz Pharmaceuticals plc

Biotechnology Innovation Organization

Miscellaneous Commercial Services

Beecken Petty O'Keefe & Co. LP

Investment Managers

Longitude Capital Management Co LLC

Investment Managers

Jazz Pharmaceuticals Ireland Ltd.

Emergent BioSolutions Ireland Ltd.

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Packaged Software3
Pharmaceuticals: Major3
Investment Managers2
Biotechnology2
Miscellaneous Commercial Services1
Airlines1
Medical Specialties1
Medical/Nursing Services1

Countries of related companies

United States45
Ireland2
United Kingdom2
Australia1
Canada1
China1
Switzerland1
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Employees
2,800
More about the company